What is claimed is:

1. A formulation for oral delivery of a kappa opioid receptor agonist, the formulation comprising: the kappa opioid receptor agonist and an absorption enhancer, wherein the kappa opioid receptor agonist is CR845 (D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-aminopiperidine-4carboxylic acid)]-OH) and the absorption enhancer comprises a medium chain fatty acid glyceride, wherein the medium chain fatty acid is selected from caproic, caprylic and capric acids.

~~2. The formulation according to claim 1, wherein the kappa opioid receptor agonist is CR845 (D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-aminopyperidine-4carboxylic acid)]-OH).~~

~~3~~2. The formulation according to claim ~~2~~ 1, wherein the glyceride of the medium chain fatty acid is a glyceride of caprylic and/or capric fatty acids.

~~4~~3. The formulation according to claim ~~2~~ 1, wherein the glyceride of the medium chain fatty acid is a triglyceride of caprylic and/or capric fatty acids.

~~5~~4. The formulation according to claim ~~3~~2, further comprising capric acid.

~~6~~5. The formulation according to claim ~~3~~2, further comprising sodium caprate.

~~7~~6. The formulation according to claim ~~3~~ 2, wherein the kappa opioid receptor agonist is embedded in a particle comprising trehalose.

~~8~~7. The formulation according to claim ~~3~~2, further comprising a chelating agent, wherein the chelating agent is succinic acid or EDTA.

~~9~~8. The formulation according to claim ~~3~~2, wherein the kappa opioid receptor agonist is from ~~about~~ 0.01% to ~~about~~ 5% (w/w) of the formulation, and wherein the formulation comprises from ~~about~~ 25% to ~~about~~ 92% (w/w) of a triglyceride of caprylic and/or capric fatty acids.

~~10~~9. The formulation according to claim ~~9~~8, comprising from ~~about~~ 5% to ~~about~~ 20% (w/w) of capric acid.

~~11~~10. The formulation according to claim ~~9~~8, comprising from ~~about~~ 5% to ~~about~~ 20% (w/w) of sodium caprate.

~~12~~11. A pharmaceutical composition, comprising the formulation according to claim ~~17~~1 and a pharmaceutically acceptable excipient, diluent or binder.

~~13~~12. The pharmaceutical composition according to claim ~~12~~11 in an enterically coated capsule or a capsule having intrinsically enteric properties.

~~14~~13. A formulation for oral delivery of a kappa opioid receptor agonist, comprising a kappa opioid receptor agonist and a glyceride of one or more medium chain fatty acids selected from the group consisting of caproic, caprylic and capric acids, wherein the kappa opioid receptor agonist is embedded in trehalose.

~~15~~14. The formulation for oral delivery of a kappa opioid receptor agonist according to claim ~~14~~13, wherein the CR845 (D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-aminopiperidine-4carboxylic acid)]-OH) of the formulation exhibits a stability greater than 96% after storage for a year at 25 ºC.